# GSK Type: Company Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/gsk Canonical HTML page: https://gethealthbrief.com/entity/gsk ## Timeline - **2026-04-01**: Data Review — Health authorities begin reviewing uptake rates and digital health records. - **2026-03-25**: Peak Delivery Phase — High-volume vaccination sessions scheduled to capture maximum student participation. - **2026-03-18**: Rollout Launch — Vaccination clinics open on campus for the first cohort of 5,000 students. - **2026-03-17**: Strain Confirmation — Laboratory results confirm Meningitis B as the causative agent in two fatal cases. - **2026-03-17**: Public Health Mobilization — Coordinated media briefings and emergency triage protocols established in affected regions. - **2026-03-16**: National Alert Issued — Health chiefs issue an 'unprecedented' warning to the NHS network. - **2026-03-15**: Initial Cluster Detection — Regional health boards report unusual spikes in bacterial meningitis cases. - **2026-03-10**: Outbreak Detected — Initial cases reported with severe symptoms; public health investigation launched. - **2026-02-26**: FY 2025 Earnings — Wave and Collegium release full-year financial results and 2026 guidance. - **2026**: Anticipated Filing — Expected regulatory submission for WVE-N531 in Duchenne muscular dystrophy. - **2025-Q4**: RNA Editing Milestone — WVE-006 demonstrates successful RNA editing in AATD patients. - **2025-Q2**: DMD Breakthrough — Wave reports industry-leading dystrophin expression for WVE-N531. - **2015-09-01**: Vaccine Integration — UK becomes first to add MenB vaccine (Bexsero) to routine infant schedule. ## Recent coverage (8 stories) ### Wave's Obesity siRNA Shows 16.5% Visceral Fat Improvement, Targeting 175M Patients 2026-08-04 03:59:45 · Sentiment: Neutral · Impact: 5/10 · Sources: 2 Wave Life Sciences' WVE-007, a novel siRNA silencing Activin E, demonstrated a 16.5% improvement in visceral fat-to-muscle ratio in Phase I, outpacing existing therapies and offering a potential solution for the 70% of GLP-1 users who discontinue within a year. With enrollment underway in the INLIGHT Phase IIa trial, the 175 million individuals with obesity in the U.S. and Europe may soon have a longer-lasting, disease-modifying option. Full story: https://gethealthbrief.com/story/wave-obesity-siRNA-16-5-vmr ### AZN-BMS $400B Talks: What It Means for Drug Prices and Access 2026-08-02 23:37:50 · Sentiment: Neutral · Impact: 9/10 · Sources: 2 A potential $400 billion merger between AstraZeneca and Bristol Myers Squibb could reshape oncology competition, with implications for drug costs, patient access, and payer negotiations. The combined portfolio would dominate key cancer markets. Full story: https://gethealthbrief.com/story/astrazeneca-bms-merger-pricing-access ### Meningitis Vaccination Campaign Targets 5,000 Students in Campus Rollout 2026-03-18 19:30:55 · Sentiment: Neutral · Impact: 5/10 · Sources: 2 A large-scale public health initiative has launched to vaccinate 5,000 university students against meningitis, addressing a critical risk demographic in communal living environments. The rollout marks a significant push by health authorities to prevent outbreaks during the peak academic season. Full story: https://gethealthbrief.com/story/meningitis-vaccine-rollout-university-campus-2026 ### UK Health Officials Alerted to 'Explosive' Meningitis Outbreak 2026-03-17 22:18:20 · Sentiment: Very Bearish · Impact: 8/10 · Sources: 3 Health authorities are mobilizing to contain a rapidly escalating meningitis outbreak characterized as 'explosive' and 'unprecedented.' The surge is forcing a massive reallocation of public health resources and a critical review of current vaccination protocols. Full story: https://gethealthbrief.com/story/uk-meningitis-outbreak-explosive-unprecedented ### Meningitis B Confirmed in Fatal Outbreak: Public Health and Vaccine Implications 2026-03-17 10:05:25 · Sentiment: Very Bearish · Impact: 7/10 · Sources: 2 Health authorities have confirmed that Meningitis B is the strain responsible for a recent outbreak that has resulted in two fatalities. The identification triggers immediate public health protocols, including targeted vaccination and antibiotic prophylaxis for close contacts to prevent further spread. Full story: https://gethealthbrief.com/story/meningitis-b-confirmed-fatal-outbreak-analysis ### Maternal Vaccine Rollout Feasible but Hindered by Infrastructure Gaps 2026-03-10 05:48:43 · Sentiment: Neutral · Impact: 5/10 · Sources: 2 A new feasibility study indicates that maternal immunization programs can be successfully integrated into existing antenatal care frameworks, provided systemic gaps are addressed. Key challenges include cold chain logistics, healthcare worker training, and the need for digital tracking systems to monitor neonatal outcomes. Full story: https://gethealthbrief.com/story/maternal-vaccine-rollout-feasibility-study-gaps ### CDC Issues Travel Advisories for Tourist Hubs Amid Global Polio Resurgence 2026-03-04 18:36:27 · Sentiment: Bearish · Impact: 7/10 · Sources: 2 The CDC has issued a series of travel notices for popular international tourist destinations following a spike in polio detections. The move signals a shift in global health security, requiring travelers to verify immunization status and potentially seek adult boosters before departure. Full story: https://gethealthbrief.com/story/cdc-polio-travel-advisories-2026 ### Wave Life Sciences and Collegium Report 2025 Results Amid RNA Breakthroughs 2026-02-26 14:24:42 · Sentiment: Neutral · Impact: 5/10 · Sources: 2 Wave Life Sciences and Collegium Pharmaceutical released their Q4 and full-year 2025 results, highlighting a pivotal year for RNA editing and specialty pain management. Wave's transition toward a commercial-stage biotech is accelerated by its GSK partnership and landmark clinical data in Alpha-1 antitrypsin deficiency. Full story: https://gethealthbrief.com/story/wave-life-sciences-collegium-2025-financials-rna-editing --- This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.